Ultragenyx Pharmaceutical | RARE - Sales Revenues


Ultragenyx Pharmaceutical reported $136M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Kyowa Hakko Kirin JPY 118.47B 28.91B Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Moderna USD 389M 289M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xoma USD 25K 5M Sep/2024